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SulTlnlary 
Murine T  cells expressing Va5 are characterized by (a) intrathymic deletion in the presence of 
I-E and products of endogenous mouse mammary tumor viruses, and (b) a greater representation 
in CD8 § relative to CD4 + peripheral T cells, thought to be due to more efficient intrathymic 
positive selection on class I rather than class II major histocompatibility complex antigens. We 
have engineered mice that are transgenic for a rearranged gene encoding a Va5 + B chain of the 
T  cell receptor for antigen. Deletion is not predicted in I-E- Va5 + transgenic mice, and until 
the age of 2 wk, the CD4/CD8 ratio of peripheral T cells is >3:1 and indistinguishable between 
transgenic and nontransgenic mice. Transgenic mice then show a rapid, age-dependent decline 
in the ratio of CD4 + to CD8 + T  cells in the lymphoid periphery, reaching a low of 1:10 by 
7 mo of age. Furthermore, the percent of peripheral CD4 + cells that express the transgene drops 
with age, reaching a low of about 60% at 7 mo, while the percent of CD8 + cells that express 
Va5 remains greater than 95% at all ages. The lymphoid periphery is implicated in this selection 
against CD4 + Va5 + T  cells as it occurs more rapidly in thymectomized transgenic mice, and 
can be delayed in mice whose peripheral T  cells are replaced by recent thymic emigrants after 
depletion by in vivo treatment with anti-Thy-1 antibodies. These results indicate that the relative 
expression of Va5 in T  cell subsets can be influenced not only intrathymically in I-E+Va5 + 
transgenic mice, but also by events in the periphery, in the absence of I-E expression. 
though helper and cytotoxic T  cells differ in function, 
accessory  molecule  expression,  MHC  restriction 
specificity, and antigen recognition, they express largely over- 
lapping V~ and Va TCR genes. One apparent exception to 
this  rule is  the observation  that  V~5  expression is  lower 
among CD4 + compared with CD8 + T  cells in mice that 
do not express I-E (1, 2). Thus, in an adult C57BL/6 mouse, 
"~10-12% of CD8 + peripheral T cells are Va5 § , compared 
with only 3-5%  of CD4 + peripheral T  cells. This skewed 
Va  expression  has  been  documented for both  functional 
members of the Va5 family, Va5.1 and Va5.2 (2), and has 
been taken to mean that regardless of the coexpressed ce chain, 
cells expressing V~5 + TCIL are more efficiently positively 
selected on class I than on class II MHC  (2). 
Other studies have indicated that Va5.1 + and Va5.2 + cells 
are deleted intrathymically in mice that express I-E molecules 
and a "cotolerogen," originally named Etc-1 (3). Intrathymic 
deletion in this (2) and many other cases (see reference 4 for 
review) results in the elimination of cells of both CD4 + and 
CD8 +  phenotypes  expressing  high  levels  of TCR,  sug- 
gesting the signal for deletion is delivered to a thymocyte 
population bearing both accessory molecules. It is now known 
that Etc-1 encodes an endogenous mammary tumor provirus 
(Mtv), Mtv-9, and that the open reading frame of the 3' long 
terminal repeat of this defective viral integrant encodes the 
"self~'-determinant that deletes Va5 + cells in I-E + mice (5, 
6). A second endogenous retroviral integrant, Mtv-6, has re- 
cently been implicated in I-E-mediated deletion of V~5.1 + 
and V~5.2 + TCK (7). 
To  study the expression of V~5 in T  cells in I-E + and 
I-E- mice and the relationship between Va5 expression and 
CD4 and CD8 positivity, we engineered mice transgenic for 
a rearranged V~5.2 ~  chain of the TCK (8).  Our work il- 
lustrates that chronic selective forces can operate on mature 
T  cells after they have left the thymus. 
Materials  and Methods 
Mice.  V~5 +  transgenic  mice  were  derived  on  a  congenic 
C57BL/6 background (H-2K  b§  I-E-, Mtv-6-, Mtv-9 +) by in- 
jection of a rearranged genomic fl chain gene from the CD8 + 
cytotoxic T cell clone B3, specific  for chicken OVA and H-2K  b (9). 
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endogenous promoter and enhancer. Two lines of independently 
derived mice were used throughout these studies, both carrying 
5-10 copies of the transgene, and both transmitting the transgenes 
in a Mendelian  fashion (8). V~5 + transgenic mice were maintained 
as heterozygotes  by crossing with C57BL/6 females  purchased from 
The Jackson Laboratory  (Bar Harbor, ME). Weanlings  were screened 
for transgene expression in PBL using a mAb specific for VaS.1 
and Vt~5.2 (10). Control nontransgenic mice were offspring from 
these same matings. I-E §  + transgenic mice were derived by 
mating heterozygous Va5 transgenic mice with line 107-1 (11), 
a line of E~ transgenic mice demonstrating a normal pattern of 
transgene expression. PBL from offspring were screened for cell 
surface expression of both Va5 and I-E. 
Surgery.  Mice  were anesthetized  with tri-bromoethanol and ei- 
ther their thymuses  were removed  by suction or their cervical  lymph 
nodes were removed  by dissection. Wounds were closed by suture 
or wound clips. 
Cell Separation.  PBL were isolated by water lysis of whole 
heparinized blood. Cortisone-resistant thymocytes were removed 
from animals  2 d after intraperitoneal  injection  of 5 mg of  hydrocor- 
tisone acetate in ethanol and water. Care was taken to remove the 
thymus free of neighboring lymph nodes. Lymph node cells were 
derived from inguinal,  brachial, axial,  cervical, and mesenteric  lymph 
nodes. 
Antibodies and ln Vivo TCellDepletion.  MR9-4, a murine IgG 
mAb specific  for Vt~5.1 and V~5.2 (10), and H7-597, an Armenian 
hamster antibody specific  for the murine TCR 3 chain (12), were 
purified from ascites (MR9-4) or culture supematant (H7-597) over 
protein G columns and directly conjugated with fluorescein  as de- 
scribed (13). PE-conjugated anti-mouse IgG1 was purchased from 
Southern  Biotechnology  Associates, Inc. (Birmingham,  AL). 
Fluorescein-conjugated anti-mouse  I-E  (clone AMS-16), PE- 
conjugated anti-CD4, and FITC- and PE-conjugated  anti-CD8 were 
purchased from PharMingen (San Diego, CA). T24, a rat anti- 
Thy-1 mAb (14), was used as unpurified ascites for the in vivo elimi- 
nation of  peripheral T cells. In vivo titration ofT24 was performed 
by intraperitoneal injection of graded doses of unpurified ascites 
once or twice into C57BL/6 mice. The e~cacy of T cell elimina- 
tion was judged by analysis of lymph node ceUs removed 3-5 d 
after the last injection. Cells were stained with anti-T cell reagents 
(anti-Thy-1, anti-CD4, anti-CDS, H7-597) and analyzed by flow 
cytometry. Cells were also assayed for their ability to proliferate 
to the T cell mitogen Con A. A >10-fold decrease in the number 
and proliferative  capacity  of T cells from injected  mice was achieved 
using the following protocol. Animals of the indicated ages were 
prebled, injected intraperitoneally with 100 gtl of unpurified T24 
ascites, rested 1 d, given a second injection of 100/~l of ascites, 
and bled again 5 d later to test the effectiveness  of the treatment. 
In each experiment, thymectomized transgenic and nontransgenic 
animals were also treated to test the dependence of T cell recovery 
on a functional thymus. 
Antibody Staining and Cell Analysis.  From 0.3 to  1.0  x  106 
cells were incubated on ice with the appropriate dilution of anti- 
body for 20 rain in HBSS with 1% BSA in a total volume of 100 
/zl, washed with 1.5 ml, and incubated under the same conditions 
with each subsequent stage. After  the  final wash, cells were 
resuspended in 0.5 ml PBS and analyzed on a FACScan  |  (Becton 
Dickinson & Co., Mountain View, CA) using Lysis  II or Consort 
30 software. With the exception of the rare subpopulations, 104 
live gated cells were analyzed in each case. Data are presented on 
a logarithmic scale. 
Results and Discussion 
The CD4/CD8 Ratio in T Cells from Young V~5 Transgenic 
Mice Is  Indistinguishable from  That  in  Young Nontransgenic 
Animals.  The preferential  expression of Vt~5 among CD8 + 
relative to CD4 § peripheral T  cells in I-E-  strains of mice 
led us to analyze the ratio of CD4 + to CD8 + T  cells in 
Va5 + TCR  transgenic mice.  Not  surprisingly, while the 
CD4/CD8  ratio  in  PBL  from  12-wk-old  nontransgenic 
animals is ~3, that of PBL from age-matched transgenic lit- 
termates is <0.4 (Fig.  1 a). These differences are equally ap- 
parent in peripheral T cells from spleen and lymph node (data 
not shown) as well as PBL. In contrast to these data from 
adult animals,  in pups from 5 d to 2 wk of age,  the ratio 
of CD4 to CD8 expression  in spleen cells from transgenic 
and nontransgenic animals is indistinguishable. The CD4/ 
CD8 ratio in the eight transgenic and eight nontransgenic 
5-d-old pups examined was 6.3 and 7.1, respectively. At 7 d, 
two pups of each type were examined, with an average ratio 
of 5.6 for transgenic and 5.7 for nontransgenic. The average 
ratios for 13-d-old pups were 1.8 (for seven transgenic pups) 
and 2.3 for (three nontransgenic pups), with the disparity 
between transgenic and nontransgenic mice increasing there- 
after. Aside from the initial drop in the ratio of CD4 to CD8 
expression  during the first few weeks after birth, the mean 
ratio in nontransgenic mice is relatively constant, at ",~2-3:1. 
In  contrast,  transgenic  mice  are  characterized  by  high 
CD4/CD8 ratios in young animals that drop >30-fold to 
a low of 0.1 at ,,o7 mo of age (Fig.  1 a). The age-dependent 
decline in the ratio of CD4/CD8 expression  seems to be a 
result of a decrease in the number of CD4 + T  cells rather 
than  an  increase  in  the  number  of CD8 +  T  cells.  The 
number of CD8 + lymph node cells is relatively constant be- 
tween age-matched transgenic and nontransgenic mice, while 
the number of CD4 + cells is much lower in the transgenic 
animals (data not shown). 
The  CD4 + Population of Peripheral T  Cells in  Transgenic 
Animals Shows a Marked, Age-related Decrease in VB5 Expres- 
sion, while the CD8 + Population Does Not.  We analyzed the 
expression of Va5 in CD4 + and CD8 + T cells in transgenic 
animals from the ages of 5 d to 45 wk (Fig.  1 b). In animals 
2 mo of age and younger, >95% of both CD4 + and CD8 + 
populations  of  peripheral  T  cells  are  V~5 +  by  surface 
staining. As these animals age, there is no detectable change 
in the transgene expression in CD8 § T cells; however, there 
is a marked decrease in the percent of CD4 + cells that ex- 
press  the  transgene.  By 6  mo  of age,  as  few as  60%  of 
CD4 + peripheral T cells from transgenic animals are V~5 § 
(Fig.  1 b). Most of the remaining '~40% of CD4 + cells ex- 
press a TCR oe//~ as judged by bright staining with H7-597 
(data not shown). 
The Age-dependent Loss of CD4 +  V#5 + Cells Occurs in the 
Lympkoid Pe@hery and Not in the  Ttrymus.  To determine 
whether the selection against V~5 expression among CD4 + 
T  cells occurs intrathymically, we first analyzed thymocyte 
subpopulations for signs of deletion of Vt~5  +  CD4 + cells in 
I-E- and I-E + TCR. transgenic mice. From the data shown 
1734  Peripheral  Modulation of the TCR Repertoire I0 
8 
6 
4 
m-- 
2 
I 
Z 
0.8 
a 
o 
0.6 
o 
o_ 
O.Z 
b 
I00- 
80 
~_  6o 
2>~--- 
'40 
20 
o  o 
N 
￿9  I  I 
0 
o 
o 
o  8 
0  oO 
o 
o  o 
o  o  o  8 
0  Oo 8o 
o 
0 
￿9  I 
Ii 
:'I 
0 
0  0 
0 
0  0  0 
0 
o  nontransgenic 
￿9  tronsgenic 
[] 
0 
0 
oo  g 
0  o 
o 
u 
::  " 
￿9 ;  ,,  ￿9 
￿9  ￿9  _mI  ￿9 
III 
I  I  I  ~  '  II  l 
10  20  30 
WEEKS  OF AGE 
￿9  ii  I 
￿9 
i  I  r 
10 
~  ~  ~176  ..'  " 
fl  ~  o  [] 
o  ~  o  Oo 
8o  oo  []  o 
o  ~ 
o 
o 
B  0  0 
~ o 
o 
o 
0 
0 
0 
0 
o CD4 positive 
￿9 CD8 positive 
'  /0  '  2'o  '  30'  '  4'0  ' 
WEEKS OF AGE 
Figure  I.  In Va5 transgenic mice,  both the CD4/CD8  ratio and the 
percent of CD4 + PBL that are also Va5 + decline with age.  (a) Relative 
CD4 and CD8 expression in peripheral T  cells from transgenic and non- 
transgenic mice. Splenocytes from 5-, 7-, and 13-d-old pups and PBL from 
4-45-wk-old  V~5 transgenic and nontransgenic animals were stained with 
FITC-MR9-4  and  anti-CD4-PE  or  anti-CD8-PE  and  analyzed  with  a 
FACScan |  (b) Transgene  expression  in CD4 +  and CD8 +  peripheral T 
cells. Cells from transgenic mice collected and stained as in a were gated 
for PE + (CD4 + or CD8 +) and then analyzed for Va5 expression. At least 
2,000  PE §  events  were analyzed from  pups  5,  7,  and  13 d  of age;  104 
gated  events  were  analyzed  for samples  from  older  animals. 
in Fig.  2 a,  it is clear  that the mature,  Vfl5 high population 
of thymocytes  is  deleted  in  I-E+V~5+Mtv-9 +  transgenic 
mice but not in their I-E-  counterparts.  These data are in 
agreement  with  previous  work  showing  that  in  mice  ex- 
pressing both Mtv-9 and I-E, deletion of V05 + cells occurs 
in the thymus,  at the time of transition from the TCR  duu, 
CD4 + CD8 +  to  the  TCR  high,  CD4 +  or  CD8 +  stage  (2). 
The incomplete,  slow deletion of CD4 +  V05 + ceils in I-E- 
transgenic animals does not occur at this same stage of devel- 
opment. 
Furthermore, the CD4/CD8 ratio of"mature" cortisone- 
resistant thymocytes pooled from two 33-wk-old transgenic 
mice is 1.9, similar to the value of 2.4 obtained from a pool 
of two age-matched nontransgenic animals (Fig. 2 b). In con- 
trast,  lymph node cells from untreated littermates  showed 
the expected decrease in the ratio of CD4/CD8 in the trans- 
genie (0.2) compared with the nontransgenic animal  (1.4). 
In  33-wk-old  transgenic  animals,  97%  of  CD4+CD8 - 
thymocytes  are VO5 +,  while  only  79%  of CD4 +  lymph 
node cells are Va5 +  (data not  shown). 
We next sought direct evidence that the lymphoid periphery 
influences  the percent of CD4 + transgene-expressing  T cells. 
We analyzed  both the CD4/CD8  ratio  and V#5 expression 
in transgenic animals that had been thymectomized at 6 wk 
of age. By analyzing these parameters at increasing times after 
thymectomy, we can observe what happens when peripheral 
T  calls "age;' in the absence of recent thymic emigrants.  In 
adult  thymectomized  animals,  the percent  of CD4 +  PBL 
that express  the transgene  decreases  dramatically,  reaching 
a low  of <40%,  compared  with  a low  of 70%  for age- 
matched nonthymectomized control transgenics  (Fig. 3 a). 
As in nonthymectomized animals, the percent of CD8 + cells 
that are V05 § remains  uniformly high,  at >95%  (data not 
shown).  Thus,  thymectomy  appears to accelerate  the dele- 
tion of CD4 + V/)5 + T cells,  while having no effect on Va5 
expression in CD8 §  cells. 
In the last series of experiments, peripheral  T  cells were 
depleted  in  28-32-wk-old  nonthymectomized  transgenic 
animals  by in vivo  treatment with anti-Thy-1  mAbs.  This 
protocol eliminates T cells from the spleen and lymph nodes, 
while causing minimal diminution in the size of the thymus 
(15,  and data not shown). Before anti-Thy-1  injection, PBL 
from  the  transgenic  animals  showed  the  expected  low 
CD4/CD8  ratio  (0.10-0.13)  with  20-30%  of CD4 + cells 
expressing a TCR fl chain gene other than Va5  (Fig.  3  b, 
and data not shown). Analysis of PBL 5 d after the final in- 
jection of anti-Thy-1  revealed that an average of only 7% of 
the original number of CD4 + or CD8 + T cell populations 
survived the anti-Thy-l-mediated  elimination.  Over the course 
of the next 7-11 wk, the animals were allowed to replenish 
their populations of peripheral T cells, to determine whether 
replacing "old" peripheral T cells with recent thymic emigrants 
can reverse the depletion of transgene-expressing CD4 + pe- 
ripheral T cells.  Only H7-597 + (TCR c~/~/+) cells were in- 
cluded in these analyses,  as the percent of Thy-1 + cells that 
are also H7-597 + varied considerably  from mouse to mouse 
(data not shown).  Depletion  of peripheral  T  cells reversed 
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Hgure  3.  The loss of CD4+Va5 + PBL is accderated by thymectomy 
and delayed by temporary elimination of peripheral T cells. (a) Mice were 
thymectomized at 6 wk of age, bled at various times postthymectomy, 
and PBL stained with FITC-MR9-4 and anti-CD4-PE. The arrow above 
Tx indicates the time of thymectomy. (b) Transgenic mice 28-32 wk of 
age were prebled and injected twice with anti-Thy-1 antibodies.  PBL or 
lymph node cells were stained with anti-CD4-PE  and either FITC-MR9-4 
or FITC-H7-597.  PE § cells were analyzed for FITC staining.  Values are 
the age-dependent loss of CD4+V~5 + cells, leaving injected 
mice with a population of H7-597 + peripheral T  cells that 
were >90% positive for Va5 expression  (Fig.  3 b). The ratio 
of CD4/CD8  expression also increased  markedly,  reaching 
an average of 1.6 at 8.5 wk postinjection (data not shown). 
No change in V~5 expression was detectable in the CD8 + 
population of peripheral T cells from injected mice (data not 
shown). 
What  Causes  the Decline  in  the CD4/CD8  Ratio  and the 
Gradual  Loss of CD4 +  V~5 + Cells  in Transgenic Mice?  The 
driving  force  for both  is  most  likely  a  selection  against 
CD4+Va5 + ceils,  resulting in a rapid,  early dedine in the 
CD4/CD8  ratio  of peripheral  T  cells and the eventual  ap- 
pearance  of CD4+V~5 -  cells  after  expansion  of  a  small 
number  of preexisting  CD4 +  ceils  that  do  not  express  a 
Va5 +  TCR.  This  newly  expanded  T  cell  population  is 
H7-597 + , indicating surface expression  of a TCR o~/~ (data 
not shown).  Previous  analyses  of TCR/3  chain transgenic 
mice (16) and mice transgenic for both ol and/3 chain genes 
corrected for the percent of Thy-1 + cells in each animal that were also 
H7-597",  to diminate TCR-  Thy-1 + cells from consideration.  Values 
at 36 and 38 wk for uninjected animals represent the average _+ SD from 
four and three age-matched animals, respectively. All other points are de- 
rived from individual animals. The arrow above Ab indicates the time of 
antibody injection. 
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exclusion of oe chain genes is leaky,  that  of 3  chain genes 
is nearly absolute. Our finding that up to 40% of peripheral 
CD4 + T  cells in old but otherwise unmanipulated  3  chain 
transgenic  animals  can express endogenously rearranged/3 
chain genes is indicative of the power of the peripheral selec- 
tion we have analyzed.  Use of endogenous c~ and 3  chain 
genes  has  recently  been  documented  in  TCR  oe/3 
transgenic mice bearing inappropriate MHC molecules (18). 
The selection against CD4+Va5 + cells is not an idiosyn- 
cracy of the particular  transgene we have chosen to study, 
since both Va5.1 and Va5.2 expression decline with age in 
CD4 + but not CD8 + peripheral T  cells from nontransgenic 
animals (data not shown). In vivo anti-Thy-1  treatment im- 
plicates the lymphoid periphery in this selection, just as in 
transgenic  mice (data not  shown). 
Why then are the CD4+Va5 + cells selected against? Our 
unpublished observations that expression of the memory cell 
marker  Pgp-1  (19)  is  high  among  CD4+Va5 +  T  cells  in 
transgenic  mice,  and that  these cells  are mildly anergic  to 
signals  through their TCR, have suggested that CD4 +  Va5 + 
cells may be stimulated by their antigen,  rendered anergic, 
and then  disappear  (20).  One candidate  antigen  is Mtv-9, 
already well documented to delete Vt35  + thymocytes in I-E + 
animals  (5-7,  and Fig.  2 a).  Perhaps in the absence of I-E, 
Mtv-9  no  longer  mediates  intrathymic  deletion  (of both 
CD4 + and CD8 + single-positive cells) but instead causes the 
progressive, peripheral deletion of CD4 + cells that we see. 
We are currently  deriving  I-E-Mtv-6/9-Va5 +  transgenic 
mice to test this  hypothesis. 
Can Selection against CD4+V#5 + Peripheral Cells  Wholly 
Account for the Skewed Expression of V#5 among CD8 + Rela- 
tive to CD4 + Peripheral Cells?  If this skewed expression is 
due solely to the weak positive selection of Va5 + TCR on 
class II relative to class I MHC, one would predict that this 
skewing would be stable,  without regard for the age of the 
animal in question.  Our results add another  level of com- 
plexity to this picture, but do not rule out the notion of the 
enhanced positive selection of Va5 + TCR on class I.  Even 
as early as day 5 of neonatal life, Ve5 expression is skewed 
toward the CD8 + population of peripheral  T  cells in non- 
transgenic mice (data not shown). Furthermore,  in 11- and 
33-wk-old nontransgenic  animals  there is an enhanced ex- 
pression of Va5 in hydrocortisone-resistant CD8 + relative to 
CD4 + thymocytes (,,o15%  vs. 5%; data not shown). These 
data are in agreement with the notion that class II is ineff~dent 
at positively selecting Va5 + TCR intrathymically,  and sug- 
gest that class II and some peripherally expressed antigen also 
serve to modulate the TCR. repertoire of mature T cells. This 
latter means of manipulating the expressed repertoire of TCR 
can cause profound alterations in the population of T  cells 
available  during  the lifetime of the animal. 
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